Comparison Overview

LLX Solutions LLC

VS

Grifols

LLX Solutions LLC

1400 Main St, Waltham, Massachusetts, 02451, US
Last Update: 2025-03-05 (UTC)
Between 800 and 900

Strong

LLX Solutions, a biopharmaceutical services company, provides clinical trial design and Protocol development, statistical analysis, programming, data management and Consulting services to the pharmaceutical, biotechnology, and medical device industries. Its team has proven expertise in supporting global clinical trials for different sizes of companies in the United States in various therapeutic categories such as cardiology, oncology, rare disease, medical devices, pain, infectious diseases, neurology, allergy/immunology, endocrinology/metabolism, gastroenterology and pediatrics. LLX Solutionsโ€™ core competencies are its employees. The key members have over 12 years experience in the industry and have built excellent reputations in the companies they severed. They have been working and providing consultant services for various biotech and pharmaceutical companies such as Wyeth/Pfizer, Shire, Genzyme, Altus, Ariad, Synta, Boston Scientific, etc. With this background, LLX Solutions is committed to provide our clients with the highest quality and timely deliverables. We are dedicated to ensuring that our clients will get the best services from us. The company was founded in 2011 and is headquartered in Waltham, Massachusetts.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 83
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Grifols

Parc Empresarial Can Sant Joan, Sant Cugat del Vallรจs, Barcelona, 08174, ES
Last Update: 2025-05-06 (UTC)

Strong

Between 800 and 900

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIMEโ€™s โ€˜Worldโ€™s Best Companiesโ€™ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,780
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/llx-solutions-llc.jpeg
LLX Solutions LLC
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
LLX Solutions LLC
100%
Compliance Rate
0/4 Standards Verified
Grifols
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for LLX Solutions LLC in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Grifols in 2025.

Incident History โ€” LLX Solutions LLC (X = Date, Y = Severity)

LLX Solutions LLC cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/llx-solutions-llc.jpeg
LLX Solutions LLC
Incidents

No Incident

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
Incidents

No Incident

FAQ

Both LLX Solutions LLC company and Grifols company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Historically, Grifols company has disclosed a higher number of cyber incidents compared to LLX Solutions LLC company.

In the current year, Grifols company and LLX Solutions LLC company have not reported any cyber incidents.

Neither Grifols company nor LLX Solutions LLC company has reported experiencing a ransomware attack publicly.

Neither Grifols company nor LLX Solutions LLC company has reported experiencing a data breach publicly.

Neither Grifols company nor LLX Solutions LLC company has reported experiencing targeted cyberattacks publicly.

Neither LLX Solutions LLC company nor Grifols company has reported experiencing or disclosing vulnerabilities publicly.

Grifols company has more subsidiaries worldwide compared to LLX Solutions LLC company.

Grifols company employs more people globally than LLX Solutions LLC company, reflecting its scale as a Pharmaceutical Manufacturing.

Latest Global CVEs (Not Company-Specific)

Description

pwn.college DOJO is an education platform for learning cybersecurity. In versions up to and including commit 781d91157cfc234a434d0bab45cbcf97894c642e, the /workspace endpoint contains an improper authentication vulnerability that allows an attacker to access any active Windows VM without proper authorization. The vulnerability occurs in the view_desktop function where the user is retrieved via a URL parameter without verifying that the requester has administrative privileges. An attacker can supply any user ID and arbitrary password in the request parameters to impersonate another user. When requesting a Windows desktop service, the function does not validate the supplied password before generating access credentials, allowing the attacker to obtain an iframe source URL that grants full access to the target user's Windows VM. This impacts all users with active Windows VMs, as an attacker can access and modify data on the Windows machine and in the home directory of the associated Linux machine via the Z: drive. This issue has been patched in commit 467db0b9ea0d9a929dc89b41f6eb59f7cfc68bef. No known workarounds exist.

Risk Information
cvss4
Base: 9.5
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:L/SC:H/SI:H/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Adobe Experience Manager versions 11.6 and earlier are affected by a stored Cross-Site Scripting (XSS) vulnerability that could be abused by a low privileged attacker to inject malicious scripts into vulnerable form fields. Malicious JavaScript may be executed in a victimโ€™s browser when they browse to the page containing the vulnerable field. Exploitation of this issue requires user interaction in that a victim must open a malicious link. Scope is changed.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
Description

Adobe Experience Manager versions 11.6 and earlier are affected by a stored Cross-Site Scripting (XSS) vulnerability that could be abused by a low privileged attacker to inject malicious scripts into vulnerable form fields. Malicious JavaScript may be executed in a victimโ€™s browser when they browse to the page containing the vulnerable field. Exploitation of this issue requires user interaction in that a victim must open a malicious link. Scope is changed.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
Description

Adobe Experience Manager versions 11.6 and earlier are affected by a stored Cross-Site Scripting (XSS) vulnerability that could be abused by a low privileged attacker to inject malicious scripts into vulnerable form fields. Malicious JavaScript may be executed in a victimโ€™s browser when they browse to the page containing the vulnerable field. Exploitation of this issue requires user interaction in that a victim must open a malicious link. Scope is changed.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
Description

Adobe Connect versions 12.9 and earlier are affected by a URL Redirection to Untrusted Site ('Open Redirect') vulnerability. An attacker could leverage this vulnerability to redirect users to malicious websites. Exploitation of this issue requires user interaction in that a victim must click on a crafted link.

Risk Information
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:N/I:L/A:N